Silvia Fargion

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 993 citations · Full text

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

Anna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi et al. · Hepatology · 2008 · 698 citations

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

Rosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta et al. · Gastroenterology · 2016 · 650 citations · Full text

Metabolic Syndrome, Hepatology, Liver Physiology +8

Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease†

Luca Valenti, Ahmad Al‐Serri, Ann K. Daly et al. · Hepatology · 2010 · 634 citations · Full text

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Paola Dongiovanni, Salvatore Petta, Cristina Maglio et al. · Hepatology · 2014 · 524 citations · Full text